GRAL

#1888
GRAIL, Inc. Common Stock
55.0200 USD
+1.10%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
55.0200
55.0200
Year Range
41.5000
102.5200
Daily Change
+1.10%
Monthly Change
+12.29%
6 month change
-44.42%
Year Change
-44.42%
Previous Close
54.4200
Open
55.0200
Low
55.0200
High
55.0200
Volume
57
Open full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 2.2569 B
  • Employee 910
  • Founded 2015
  • CEO N/A
  • Website www.grail.com
  • Headquarter Delaware, United States
  • FIGI BBG01N6CGW43
  • Industry Diagnostics & Research
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-7.7
Price to sales ratio
21.37

GRAIL Inc

GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021. In June 2021 GRAIL launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024.